Drug Profile
Naptumomab estafenatox - Active Biotech/NeoTX Therapeutics
Alternative Names: ABR-217620; Anyara; NAP - Active Biotech/NeoTx Therapeutics; NTX 352; TTS CD3Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Active Biotech
- Developer Active Biotech; NeoTX Therapeutics
- Class Antineoplastics; Drug conjugates; Fab fragments; Immunotherapies; Immunotoxins; Recombinant fusion proteins
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- Phase I/II Solid tumours
- Suspended Pancreatic cancer; Renal cancer
Most Recent Events
- 30 Jan 2024 NeoTX Therapeutics completes a phase II trial in Non-small cell lung cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT04880863)
- 08 Jun 2023 NeoTX Therapeutics and Weill Medical College of Cornell University plans a phase I trial in Urogenital cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater ) in USA (IV) in June 2023 (NCT05894447)
- 19 Apr 2023 Interim efficacy & adverse events data from a phase Ib/II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) released by Active Biotech